Fundraising FoxAvenzoar Pharmaceuticals
Encinitas, US · Founded 2015 · California corporation
Find your way into Avenzoar Pharmaceuticals
Sign up to see every warm intro you have to Avenzoar Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Avenzoar Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Avenzoar Pharmaceuticals is a pharmaceutical company developing therapies through its team of scientists and researchers. The page provides team information but limited detail on specific products or focus areas.
Founders & leadership
Avenzoar Pharmaceuticals was founded in 2015 by Stephen Pandol.
ST
Stephen ThesingChief Executive OfficerHe has held leadership roles in biopharma and healthcare technology across public, venture-backed, and private equity-owned organizations.
JN
Joe NinoskyVP of Chemistry, Manufacturing, and Controls (CMC)
TB
Terrance BruggemanNamed on SEC filing
ME
Mouad EdderkaouiChief Scientific Officer & Co-Founder
DK
David KramerNamed on SEC filing
WR
William ReaveyNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 2 rounds · 2019–2023
▶$899.7KraisedJun 2023 · 2 investors · BiotechnologyRule 506(b)
▶$899.7KraisedJun 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark ChinDirector
- Shierley WidjajaDirector
- Stephen PandolDirector
- Mouad EdderkaouiDirector
- Terrance J. BruggemanExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $899.7K
- Proceeds to insiders
- $79.7K
- First sale
- May 2023
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$525.1KraisedOct 2019 · 4 investors · PharmaceuticalsRule 506(b)
▶$525.1KraisedOct 2019 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Terrance BruggemanExecutive Officer, Director
- Mouad EdderkaouiDirector
- David KramerExecutive Officer
- William ReaveyExecutive Officer
- Offering amount
- $918.2K
- Amount sold
- $525.1K
- First sale
- Oct 2019
- Incorporated
- Corporation, California, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
AvenzoAvenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments. The company focuses on oncology and cell therapy programs.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Companies working in the same space as Avenzoar Pharmaceuticals.
Frequently asked questions
- What does Avenzoar Pharmaceuticals do?
- Avenzoar Pharmaceuticals is a pharmaceutical company developing therapies through its team of scientists and researchers. The page provides team information but limited detail on specific products or focus areas.
- Who founded Avenzoar Pharmaceuticals?
- Avenzoar Pharmaceuticals was founded by Stephen Pandol in 2015.
- How much funding has Avenzoar Pharmaceuticals raised?
- Avenzoar Pharmaceuticals has disclosed $1.4M raised across 2 rounds.
- Where is Avenzoar Pharmaceuticals headquartered?
- Avenzoar Pharmaceuticals is headquartered in Encinitas, US.